Carregant...

Acquired Resistance to Targeted Therapies against Oncogene-Driven Non-Small Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications

In the emerging era of targeted therapy for advanced stage non-small cell lung cancer (NSCLC), it is becoming increasingly important to anticipate potential underlying driver oncogene alterations at the time of initial diagnosis and tumor tissue acquisition, so that patients can be selected in a tim...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Lung Cancer
Autors principals: Gandara, D.R., Li, T., Lara, P.N., Kelly, K., Riess, J.W., Redman, M. W., Mack, P.C.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4586161/
https://ncbi.nlm.nih.gov/pubmed/24176733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2013.10.001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!